TechAccel's model of matching risk capital with smart science is paying off

TechAccel CEO Michael Helmstetter says the company has more assets in its portfolio and a higher potential than originally anticipated.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 11, 2019 Category: Pharmaceuticals Authors: Leslie Collins Source Type: news